Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million

Johnson & Johnson to settle talc baby powder investigation, will reportedly pay 0 million


In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. 

Justin Sullivan | Getty Images

Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into claims that the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. 

Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which are slated to go to trial this year, alleging that those talc-based products caused cancer.

Those cases have for decades caused financial and public relations trouble for J&J, which contends that its now-discontinued talc products are safe for consumers.

J&J said in an October securities filing that 42 states and Washington, D.C., had launched a joint investigation into its marketing of talc-based products. The company will pay $700 million to settle the probe, its CFO Joseph Wolk told the Wall Street Journal Tuesday.

Last year, J&J only set aside about $400 million to resolve U.S. state consumer protection claims.

Erik Haas, J&J’s worldwide vice president of litigation, confirmed the settlement in a statement to CNBC. He did not provide the payment amount or further details on the deal.

“Consistent with the plan we outlined last year, the company continues to pursue several paths to achieve a comprehensive and final resolution of the talc litigation,” Haas told CNBC. “As was leaked last week, that progress includes an agreement in principle that the Company reached with a consortium of 43 State Attorneys Generals to resolve their talc claims.”

Bloomberg first reported about the settlement earlier this month, citing sources familiar with the matter. 

J&J, which reported fourth-quarter results on Tuesday, has twice tried to resolve the consumer talc cases by offloading those liabilities into a subsidiary, LTL Management, and having that unit file for Chapter 11 bankruptcy protection. 

A New Jersey bankruptcy judge in July rejected the second bankruptcy attempt, stating that LTL Management wasn’t in sufficient financial distress. A U.S. appeals court in April dismissed the first bankruptcy attempt for the same reason. 

As part of the latest failed bankruptcy attempt, J&J proposed to pay $8.9 billion to talc claimants.

J&J said late last year that it is considering a third bankruptcy attempt as it tries to push forward with that proposal.

J&J ended sales of its talc-based baby powder globally last year.



Source

Sarepta shares plunge 40% as future of its gene therapy appears at risk
Health

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023. Michael Nagle | Bloomberg | Getty Images Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The […]

Read More
Trump diagnosed with common vein condition after ankle swelling raises concerns
Health

Trump diagnosed with common vein condition after ankle swelling raises concerns

First Lady Melania Trump, President Donald Trump, FIFA President Gianni Infantino and his wife, Leena Al Ashqar, attend the FIFA Club World Cup 2025 final football match between England’s Chelsea and France’s Paris Saint-Germain at MetLife Stadium in East Rutherford, New Jersey, July 13, 2025. Charly Triballeau | AFP | Getty Images President Donald Trump […]

Read More
Abbott stock fell victim to an old earnings season truth: It’s all about the guidance
Health

Abbott stock fell victim to an old earnings season truth: It’s all about the guidance

Shares of Abbott Laboratories fell Thursday after the diversified health-care company delivered a solid second quarter but left investors disappointed with forward guidance. Revenue in the three months ended June 30 rose 7.4% to $11.14 billion, outpacing the $11.07 billion consensus estimate, according to estimates compiled by LSEG. Organic sales , excluding Covid testing results, […]

Read More